Levodropropizine does not affect P0.1 and breathing pattern in healthy volunteers and patients with chronic respiratory impairment

C. Bruschi, P. Crotti, E. Dacosto, F. Fanfulla, L. Daffonchio, R. Novellini

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

To evaluate whether the peripherally acting antitussive levodropropizine could affect the respiratory drive and the breathing pattern, we performed a double-blind, randomised, cross-over trial in 12 healthy volunteers and 12 patients with chronic respiratory impairment associated with chronic obstructive pulmonary disease. Levodropropizine 6% drops (at the recommended dose for adults) or placebo were administered orally t.i.d. for 10 consecutive administrations. Mouth occlusion pressure (P0.1), minute ventilation (Ve), tidal volume (Vt), respiratory rate (RR), mean inspiratory flow (Vt/Ti), end-tidal CO2 (EtCO2), oxygen saturation (SaO2), forced expiratory volume in 1 s (FEV1), and the response to a hypercapnic stimulus were measured before and 1 h after the first and the last drug administration. Levodropropizine did not modify P0.1 in basal conditions and after a hypercapnic stimulus, either in healthy volunteers or in patients. In parallel, levodropropizine did not significantly affect Vt, RR, Ve, Vt/Ti and EtCO2 in both the populations. Minor changes were induced by levodropropizine on SaO2 in healthy volunteers, which despite a statistical difference, were too low to gain a clinical significance. These results confirmed the respiratory safety of levodropropizine 6% drops administered at the recommended dosage either in healthy volunteers or patients with chronic respiratory impairment.

Original languageEnglish
Pages (from-to)231-236
Number of pages6
JournalPulmonary Pharmacology and Therapeutics
Volume16
Issue number4
DOIs
Publication statusPublished - Jul 2003

Fingerprint

Healthy Volunteers
Respiration
Tidal Volume
Respiratory Rate
Ventilation
Antitussive Agents
Pulmonary diseases
Forced Expiratory Volume
Cross-Over Studies
Chronic Obstructive Pulmonary Disease
Mouth
dipropizine
Placebos
Oxygen
Safety
Pressure
Pharmaceutical Preparations
Population

Keywords

  • Breathing pattern
  • Chronic obstructive pulmonary disease
  • Chronic respiratory impairment
  • Hypercapnic stimulus
  • Levodropropizine
  • P0.1

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology

Cite this

Levodropropizine does not affect P0.1 and breathing pattern in healthy volunteers and patients with chronic respiratory impairment. / Bruschi, C.; Crotti, P.; Dacosto, E.; Fanfulla, F.; Daffonchio, L.; Novellini, R.

In: Pulmonary Pharmacology and Therapeutics, Vol. 16, No. 4, 07.2003, p. 231-236.

Research output: Contribution to journalArticle

@article{bcfcbb6dc85f4112a19a4d29089709ec,
title = "Levodropropizine does not affect P0.1 and breathing pattern in healthy volunteers and patients with chronic respiratory impairment",
abstract = "To evaluate whether the peripherally acting antitussive levodropropizine could affect the respiratory drive and the breathing pattern, we performed a double-blind, randomised, cross-over trial in 12 healthy volunteers and 12 patients with chronic respiratory impairment associated with chronic obstructive pulmonary disease. Levodropropizine 6{\%} drops (at the recommended dose for adults) or placebo were administered orally t.i.d. for 10 consecutive administrations. Mouth occlusion pressure (P0.1), minute ventilation (Ve), tidal volume (Vt), respiratory rate (RR), mean inspiratory flow (Vt/Ti), end-tidal CO2 (EtCO2), oxygen saturation (SaO2), forced expiratory volume in 1 s (FEV1), and the response to a hypercapnic stimulus were measured before and 1 h after the first and the last drug administration. Levodropropizine did not modify P0.1 in basal conditions and after a hypercapnic stimulus, either in healthy volunteers or in patients. In parallel, levodropropizine did not significantly affect Vt, RR, Ve, Vt/Ti and EtCO2 in both the populations. Minor changes were induced by levodropropizine on SaO2 in healthy volunteers, which despite a statistical difference, were too low to gain a clinical significance. These results confirmed the respiratory safety of levodropropizine 6{\%} drops administered at the recommended dosage either in healthy volunteers or patients with chronic respiratory impairment.",
keywords = "Breathing pattern, Chronic obstructive pulmonary disease, Chronic respiratory impairment, Hypercapnic stimulus, Levodropropizine, P0.1",
author = "C. Bruschi and P. Crotti and E. Dacosto and F. Fanfulla and L. Daffonchio and R. Novellini",
year = "2003",
month = "7",
doi = "10.1016/S1094-5539(03)00053-1",
language = "English",
volume = "16",
pages = "231--236",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press",
number = "4",

}

TY - JOUR

T1 - Levodropropizine does not affect P0.1 and breathing pattern in healthy volunteers and patients with chronic respiratory impairment

AU - Bruschi, C.

AU - Crotti, P.

AU - Dacosto, E.

AU - Fanfulla, F.

AU - Daffonchio, L.

AU - Novellini, R.

PY - 2003/7

Y1 - 2003/7

N2 - To evaluate whether the peripherally acting antitussive levodropropizine could affect the respiratory drive and the breathing pattern, we performed a double-blind, randomised, cross-over trial in 12 healthy volunteers and 12 patients with chronic respiratory impairment associated with chronic obstructive pulmonary disease. Levodropropizine 6% drops (at the recommended dose for adults) or placebo were administered orally t.i.d. for 10 consecutive administrations. Mouth occlusion pressure (P0.1), minute ventilation (Ve), tidal volume (Vt), respiratory rate (RR), mean inspiratory flow (Vt/Ti), end-tidal CO2 (EtCO2), oxygen saturation (SaO2), forced expiratory volume in 1 s (FEV1), and the response to a hypercapnic stimulus were measured before and 1 h after the first and the last drug administration. Levodropropizine did not modify P0.1 in basal conditions and after a hypercapnic stimulus, either in healthy volunteers or in patients. In parallel, levodropropizine did not significantly affect Vt, RR, Ve, Vt/Ti and EtCO2 in both the populations. Minor changes were induced by levodropropizine on SaO2 in healthy volunteers, which despite a statistical difference, were too low to gain a clinical significance. These results confirmed the respiratory safety of levodropropizine 6% drops administered at the recommended dosage either in healthy volunteers or patients with chronic respiratory impairment.

AB - To evaluate whether the peripherally acting antitussive levodropropizine could affect the respiratory drive and the breathing pattern, we performed a double-blind, randomised, cross-over trial in 12 healthy volunteers and 12 patients with chronic respiratory impairment associated with chronic obstructive pulmonary disease. Levodropropizine 6% drops (at the recommended dose for adults) or placebo were administered orally t.i.d. for 10 consecutive administrations. Mouth occlusion pressure (P0.1), minute ventilation (Ve), tidal volume (Vt), respiratory rate (RR), mean inspiratory flow (Vt/Ti), end-tidal CO2 (EtCO2), oxygen saturation (SaO2), forced expiratory volume in 1 s (FEV1), and the response to a hypercapnic stimulus were measured before and 1 h after the first and the last drug administration. Levodropropizine did not modify P0.1 in basal conditions and after a hypercapnic stimulus, either in healthy volunteers or in patients. In parallel, levodropropizine did not significantly affect Vt, RR, Ve, Vt/Ti and EtCO2 in both the populations. Minor changes were induced by levodropropizine on SaO2 in healthy volunteers, which despite a statistical difference, were too low to gain a clinical significance. These results confirmed the respiratory safety of levodropropizine 6% drops administered at the recommended dosage either in healthy volunteers or patients with chronic respiratory impairment.

KW - Breathing pattern

KW - Chronic obstructive pulmonary disease

KW - Chronic respiratory impairment

KW - Hypercapnic stimulus

KW - Levodropropizine

KW - P0.1

UR - http://www.scopus.com/inward/record.url?scp=0038693138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038693138&partnerID=8YFLogxK

U2 - 10.1016/S1094-5539(03)00053-1

DO - 10.1016/S1094-5539(03)00053-1

M3 - Article

C2 - 12850126

AN - SCOPUS:0038693138

VL - 16

SP - 231

EP - 236

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

IS - 4

ER -